NF-kappaB only partially mediates Epstein-Barr virus latent membrane protein 1 activation of B cells Free

Abstract

The latent membrane protein 1 (LMP1) of Epstein- Barr virus (EBV) is required for EBV-induced immortalization of human B cells and causes tumori- genic transformation of cell lines. LMP1 expression induces phenotypic changes resembling B cell activation, such as cell size increase and up-regulation of cell surface activation markers. LMP1 contains two domains that activate the transcription factor NF-κB, one through interactions with TRAF proteins and the other with the TRADD protein. The purpose of the present study was to investigate the importance of NF-κB induction in the up-regulation of the B cell activation markers ICAM-1 andCD71 byLMP1. This study shows that expression of LMP1 activates transcription from p50/p65- and c-Rel-responsive promoters, and that this activity can be completely inhibited by expression of a dominant inhibitory IκB mutant. ICAM-1 and CD71 are nevertheless up- regulated by LMP1 in primary B cells and cell lines expressing the dominant IκB. Furthermore, LMP1- induced cell size increase of primary B cells was unaffected by IκB expression. It was concluded that even when LMP1 is unable to activate NF-κB, it is still capable of inducing certain characteristics of activated B cells, strongly suggesting that LMP1 can also activate cells independently of NF-κB.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-79-9-2117
1998-09-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/79/9/9747720.html?itemId=/content/journal/jgv/10.1099/0022-1317-79-9-2117&mimeType=html&fmt=ahah

References

  1. Anagnostopoulos I., Hummel M., Finn T., Tiemann M., Korbjuhn P., Dimmler C., Gatter K., Dallenbach F., Parwaresch M.R., Stein H. 1992; Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 80:1804–1812
    [Google Scholar]
  2. Baichwal V. R., Sugden B. 1988; Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2:461–467
    [Google Scholar]
  3. Brown K., Gerstberger S., Carlson L., Franzoso G., Siebenlist U. 1995; Control of I k B-α proteolysis by site specific, signal induced phosphorylation. Science 267:1485–1488
    [Google Scholar]
  4. Bull P., Morley K. L., Hoekstra M. F., Hunter T., Verma I. M. 1990; The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain. Molecular and Cellular Biology 10:5473–5485
    [Google Scholar]
  5. Chen C. L., Sadler R. H., Walling D. M., Su I. J., Hsieh H. C., RaabTraub N. 1993; Epstein-Barr virus (EBV) gene expression in EBV- positive peripheral T-cell lymphomas. Journal of Virology 67:6303–6308
    [Google Scholar]
  6. Corneliussen B., Holm M., Waltersson Y, Onions J., Hallberg B., Thornell A., Grundström T. 1994; Calcium}calmodulin inhibition of basic-helix-loop-helix transcription factor domains. Nature 368:760–764
    [Google Scholar]
  7. Devergne O., Hatzivassiliou E., Izumi K. M., Kaye K. M., Kleijnen M. F., Kieff E., Mosialos G. 1996; Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-KB activation. Molecular and Cellular Biology 16:7098–7108
    [Google Scholar]
  8. Epstein M. A., Achong B. G. editors 1979 The Epstein-Barr virus Berlin: Springer Verlag;
    [Google Scholar]
  9. Ernberg I., Falk K., Minarovits J., Busson P., Tursz T., Masucci M. G., Klein G. 1989; The role of methylation in the phenotype- dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. Journal of General Virology 70:2989–3002
    [Google Scholar]
  10. Fahråeus R., Fu H. L., Ernberg I., Finke J., Rowe M., Klein G., Falk K., Nilsson E., Yadav M., Busson P., Tursz T., Kallin B. 1988; Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. International Journal of Cancer 42:329338
    [Google Scholar]
  11. Fennewald S., vanSanten V., Kieff E. 1984; Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. Journal of Virology 51:411–419
    [Google Scholar]
  12. Gauwerky C., Golde D. W. 1980; Hormonal effects on cell proliferation in a human erythroleukemia cell line (K562). Blood 56:886–891
    [Google Scholar]
  13. Hammarskjöld M. L., Simurda M. C. 1992; Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus 1 long terminal repeat through induction of NF- K B activity. Journal of Virology 66:6497–6501
    [Google Scholar]
  14. Haskill S., Beg A. A., Tompkins S. M., Morris J. S., Yurochko A. D., Sampson-Johannes A., Mondal K., Ralph P., Baldwin A. S. Jr 1990; Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell 65:1281–1289
    [Google Scholar]
  15. He Q., Beyers A. D., Barclay A. N., Williams A. F. 1988; A role in transmembrane signaling for the cytoplasmic domain of the CD2 T lymphocyte surface antigen. Cell 54:979–984
    [Google Scholar]
  16. Henderson S., Rowe M., Gregory C., CroomCarter D., Wang F., Longnecker R., Kieff E., Rickinson A. 1991; Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107–1115
    [Google Scholar]
  17. Hennessy K., Fennewald S., Hummel M., Cole T., Kieff E. 1984; A membrane protein encoded by Epstein-Barr virus in latent growthtransforming infection. Proceedings of the National Academy of Sciences, USA 81:7207–7211
    [Google Scholar]
  18. Herbst H., Dallenbach F., Hummel M., Niedobitek G., Pileri S., Muller-Lantsch N., Stein H. 1991; Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proceedings of the National Academy of Sciences, USA 88:4766–4770
    [Google Scholar]
  19. Huen D. S., Henderson S. A., Croom-Carter D., Rowe M. 1995; The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF- K B and cell surface phenotype via two effector regions in its carboxy terminal cytoplasmic domain. Oncogene 10:549–560
    [Google Scholar]
  20. Izumi K. M., Kieff E. D. 1997; The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kB. Proceedings of the National Academy of Sciences, USA 94:12592–12597
    [Google Scholar]
  21. Izumi K. M., Kaye K. M., Kieff E. D. 1994; Epstein-Barr virus recombinant molecular genetic analysis of the LMP1 amino-terminal cytoplasmic domain reveals a probable structural role, with no component essential for primary B-lymphocyte growth transformation. Journal of Virology 68:4369–4376
    [Google Scholar]
  22. Jahnke A., Johnson J. P. 1994; Synergistic activation ofintercellular adhesion molecule 1 (ICAM-1) by TNF-a and IFN-y is mediated by p65/p50 and p65/c-Rel and interferon-responsive factor Stat1 a (p91) that can be activated by both IFN-y and IFN-a. FEBS Letters 354:220–226
    [Google Scholar]
  23. Kaye K. M., Izumi K. M., Kieff E. 1993; Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proceedings of the National Academy of Sciences, USA 90:9150–9154
    [Google Scholar]
  24. Kaye K. M., Izumi K. M., Mosialos G., Kieff E. 1995; The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B- lymphocyte transformation. Fibroblast cocultivation complements a critical function within the terminal 155 residues. Journal of Virology 69:675–683
    [Google Scholar]
  25. Kieff E., Liebowitz D. 1990; Epstein-Barr virus and its replication. In Fields Virology, 2nd edn. pp 1889–1920 Fields B. N., Knipe D. M. Edited by New York: Raven Press;
    [Google Scholar]
  26. Kieran M., Blank V., Logeat F., Vandekerckhove J., Lottspeich F., Le-Bail O., Urban M. B., Kourilsky P., Baeuerle P. A., Israel A. 1990; The DNA binding subunit of NF-KB is identical to factor KBF1 and homologous to the rel oncogene product. Cell 62:1007–1018
    [Google Scholar]
  27. Kieser A., Kilger E., Gires O., Ueffing M., Kolch W., Hammerschmidt W. 1997; Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO Journal 16:6478–6485
    [Google Scholar]
  28. Kilger E., Kieser A., Baumann M., Hammerschmidt W. 1998; Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO Journal 17:1700–1709
    [Google Scholar]
  29. Laemmli U. K. 1970; Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685
    [Google Scholar]
  30. Laherty C., Hu H., Opipari A., Wang F., Dixit V. 1992; The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor, k B. Journal of Biological Chemistry 267:24157–24160
    [Google Scholar]
  31. Liebowitz D., Wang D., Kieff E. 1986; Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. Journal of Virology 58:233–237
    [Google Scholar]
  32. Liebowitz D., Kopan R., Fuchs E., Sample J., Kieff E. 1987; An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes. Molecular and Cellular Biology 7:2299–2308
    [Google Scholar]
  33. Liou H. -C., Sha W. C., Scott M. L., Baltimore D. 1994; Sequential induction of NF-kB/Rel family proteins during B-cell terminal differentiation. Molecular and Cellular Biology 14:5349–5359
    [Google Scholar]
  34. Martin J., Sugden B. 1991; Transformation by the oncogenic latent membrane protein correlates with its rapid turnover, membrane localization, and cytoskeletal association. Journal of Virology 65:3246–3258
    [Google Scholar]
  35. Martin J. M., Veis D., Korsmeyer J., Sugden B. 1993; Latent membrane protein of Epstein-Barr virus induces cellular phenotype independently of expression of Bcl-2. Journal of Virology 67:5269–5278
    [Google Scholar]
  36. Mercurio F., Didonato J., Rosette C., Karin M. 1992; Molecular cloning and characterization of a novel Rel/NF- K B family member displaying structural andfunctional homologytoNF-KB p50/p105. DNA and Cell Biology 11:523–537
    [Google Scholar]
  37. Miller W. E., Mosialis G., Kieff E., Raab-Traub N. 1996; Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kB activation. Journal of Virology 71:586–594
    [Google Scholar]
  38. Mitchell T., Sugden B. 1995; Stimulation of NF-KB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. Journal of Virology 69:2968–2976
    [Google Scholar]
  39. Miyamoto S., Chiao P. J., Verma I. M. 1994; Enhanced k B-a degradation is responsible for constitutive NF-K B activity in mature murine B-cell lines. Molecular and Cellular Biology 14:3276–3282
    [Google Scholar]
  40. Mizushima S., Nagata S. 1990; pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Research 18:5322
    [Google Scholar]
  41. Moorthy R. K., Thorley-Lawson D. A. 1993; All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP1 are required for transformation of Rat-1 fibroblasts. Journal of Virology 67:1638–1646
    [Google Scholar]
  42. Mosialos G., Birkenbach M., Yalamanchili R., VanArsdale T., Ware C., Kieff E. 1995; The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80:389–399
    [Google Scholar]
  43. Muñoz C., Castellanos M. C., Arántzazu A., Vara A., Esteban M. E., Redondo J. M., Landázuri M. O. 1996; Transcriptional up- regulation of intracellular adhesion molecule-1 in human endothelial cells by the antioxidant pyrrolidine dithiocarbamate involves the activation of activating protein-1. Journal of Immunology 157:3587–3597
    [Google Scholar]
  44. Ohmori Y., Tebo J., Nedospasov S., Hamilton T. A. 1994; Kappa B binding activity in a murine macrophage-like cell line. Journal of Biological Chemistry 269:17684–17690
    [Google Scholar]
  45. Ohno H., Nakamura T., Yagita H., Okamura K., Taniguchi M., Saito T. 1991; Induction of negative signal through CD2 during antigen-specific T cell activation. Journal of Immunology 147:2100–2106
    [Google Scholar]
  46. Ouyang Q., Bommakanti M., Miskimins W. K. 1993; A mitogen- responsive promoter region that is synergistically activated through multiple signalling pathways. Molecular and Cellular Biology 13:1796–1804
    [Google Scholar]
  47. Peng M., Lundgren E. 1992; Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 7:1775–1782
    [Google Scholar]
  48. Peng M., Lundgren E. 1993; Transient expression of Epstein-Barr virus LMP1 gene in B-cell chronic lymphocytic leukemia cells, T-cells, and hematopoetic cell lines: cell type independent-induction of CD23, CD21 and ICAM-1. Leukemia 7:104–112
    [Google Scholar]
  49. Peng-Pilon M., Ruuth K., Lundgren E., Brodin P. 1995; The cytoplasmic C-terminal domain but not the N-terminal domain of latent membrane protein 1 from Epstein-Barr virus is essential for B cell activation. Journal of General Virology 76:767777
    [Google Scholar]
  50. Pierce J. W., Leonardo M., Baltimore D. 1987; Oligonucleotide that binds nuclear factor NF-KB acts as a lymphoid-specific and inducible enhancer element. Proceedings of the National Academy of Sciences, USA 85:1482–1486
    [Google Scholar]
  51. Pilon M., Gullberg M., Lundgren E. 1991; Transient expression of the CD2 cell surface antigen as a sortable marker to monitor high frequency transfection of human primary B cells. Journal of Immunology 146:1047–1051
    [Google Scholar]
  52. Rowe M., Rooney C. M., Edwards C. F., Lenoir G. M., Rickinson A. B. 1986; Epstein-Barr virus status and tumor cell phenotype in sporadic Burkitt’s lymphoma. International Journal of Cancer 37:367–373
    [Google Scholar]
  53. Rowe M., Rowe D. T., Gregory C. D., Young L. S., Farrel P. J., Rupani H., Rickinson A. B. 1987; Differences in B cell growth phenotype reflects novel patterns of Epstein-Barr virus latent gene expression in Burkitt’s lymphoma cells. EMBO Journal 6:2743–2751
    [Google Scholar]
  54. Rowe M., Peng-Pilon M., Huen D. S., Hardy R., Croom-Carter D., Lundgren E., Rickinson A. B. 1994; Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell specific response that is delayed relative to NF-KB activation and to induction of cell surface markers. Journal of Virology 68:5602–5612
    [Google Scholar]
  55. Su I. -J., Hsieh H. -C., Lin K. -H., Uen W. -C., Kao C. -L., Chen C. -J., Cheng A. -L., Kadin M. E., Chen J. -Y. 1991; Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinico- pathological and molecular analysis. Blood 77:799–808
    [Google Scholar]
  56. Sugden B. 1989; An intricate route to immortality. Cell 57:5–7
    [Google Scholar]
  57. Towbin H., Steahelin T., Gordon J. 1979; Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets : procedure and some applications. Proceedings of the National Academy of Sciences, USA 76:4350–4354
    [Google Scholar]
  58. Wang D., Liebowitz D., Kieff E. 1985; An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831–840
    [Google Scholar]
  59. Wang D., Liebowitz D., Wang F., Gregory C., Rickinson A., Larson R., Springer T., Kieff E. 1988; Epstein-Barr virus latent membrane protein alters the human B-lymphocyte phenotype : deletion of the amino terminus abolishes activity. Journal of Virology 62:4173–4184
    [Google Scholar]
  60. Zabel U., Schreck R., Baeuerle P. A. 1991; DNA binding of purified transcription factor NF- K B. Affinity, specificity, Zn2+dependence, and differential half-site recognition. Journal of Biological Chemistry 266:252–260
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-79-9-2117
Loading
/content/journal/jgv/10.1099/0022-1317-79-9-2117
Loading

Data & Media loading...

Most cited Most Cited RSS feed